Literature DB >> 14687592

Mechanisms of water and sodium retention in cirrhosis and the pathogenesis of ascites.

Andrés Cárdenas1, Vicente Arroyo.   

Abstract

Patients with advanced cirrhosis and portal hypertension often show an abnormal regulation of extracellular fluid volume, resulting in the accumulation of fluid as ascites, pleural effusion or oedema. The mechanisms responsible for ascites formation include alterations in the splanchnic circulation as well as renal functional abnormalities that favour sodium and water retention. Renal abnormalities occur in the setting of a hyperdynamic state characterized by an increase cardiac output, a reduction in total vascular resistance and an activation of neurohormonal vasoactive systems. This circulatory dysfunction, due mainly to intense arterial vasodilation in the splanchnic circulation, is considered to be a primary feature in the pathogenesis of ascites. A major factor involved in the development of splanchnic arterial vasodilation is nitric oxide (NO), a potent vasodilator that is elevated in the splanchnic circulation of patients with cirrhosis. This event decreases effective arterial blood volume and leads to fluid accumulation and renal function abnormalities which are a consequence of the homeostatic activation of vasoconstrictor and antinatriuretic factors triggered to compensate for a relative arterial underfilling. The net effect is avid retention of sodium and water as well as renal vasoconstriction. The mechanisms of sodium and water retention and ascites formation in patients with cirrhosis are discussed in this review.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14687592     DOI: 10.1016/s1521-690x(03)00052-6

Source DB:  PubMed          Journal:  Best Pract Res Clin Endocrinol Metab        ISSN: 1521-690X            Impact factor:   4.690


  14 in total

1.  Brain-Derived Neurotrophic Factor and Supraoptic Vasopressin Neurons in Hyponatremia.

Authors:  Kirthikaa Balapattabi; Joel T Little; Martha Bachelor; J Thomas Cunningham
Journal:  Neuroendocrinology       Date:  2019-09-27       Impact factor: 4.914

2.  ΔFosB in the supraoptic nucleus contributes to hyponatremia in rats with cirrhosis.

Authors:  J Thomas Cunningham; Thekkethil Prashant Nedungadi; Joseph D Walch; Eric J Nestler; Helmut B Gottlieb
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2012-05-23       Impact factor: 3.619

3.  Region-specific changes in transient receptor potential vanilloid channel expression in the vasopressin magnocellular system in hepatic cirrhosis-induced hyponatraemia.

Authors:  T P Nedungadi; F R Carreño; J D Walch; C S Bathina; J T Cunningham
Journal:  J Neuroendocrinol       Date:  2012-04       Impact factor: 3.627

4.  Intracerebroventricular losartan infusion modulates angiotensin II type 1 receptor expression in the subfornical organ and drinking behaviour in bile-duct-ligated rats.

Authors:  Joseph D Walch; Flávia Regina Carreño; J Thomas Cunningham
Journal:  Exp Physiol       Date:  2012-12-13       Impact factor: 2.969

5.  Altered central TRPV4 expression and lipid raft association related to inappropriate vasopressin secretion in cirrhotic rats.

Authors:  Flávia Regina Carreño; Lisa L Ji; J Thomas Cunningham
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2008-12-17       Impact factor: 3.619

6.  ANG II receptor subtype 1a gene knockdown in the subfornical organ prevents increased drinking behavior in bile duct-ligated rats.

Authors:  Joseph D Walch; T Prashant Nedungadi; J Thomas Cunningham
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2014-07-09       Impact factor: 3.619

7.  Sex Differences in the Regulation of Vasopressin and Oxytocin Secretion in Bile Duct Ligated Rats.

Authors:  Kirthikaa Balapattabi; Joel T Little; Martha E Bachelor; Rebecca L Cunningham; J Thomas Cunningham
Journal:  Neuroendocrinology       Date:  2020-04-24       Impact factor: 4.914

8.  Albumin May Prevent the Morbidity of Paracentesis-Induced Circulatory Dysfunction in Cirrhosis and Refractory Ascites: A Pilot Study.

Authors:  Hiang Keat Tan; Paul Damien James; Florence Wong
Journal:  Dig Dis Sci       Date:  2016-04-05       Impact factor: 3.199

9.  Clinical manifestations of portal hypertension.

Authors:  Said A Al-Busafi; Julia McNabb-Baltar; Amanda Farag; Nir Hilzenrat
Journal:  Int J Hepatol       Date:  2012-09-17

10.  Conivaptan: a step forward in the treatment of hyponatremia?

Authors:  Su Su Hline; Phuong-Truc T Pham; Phuong-Thu T Pham; May H Aung; Phuong-Mai T Pham; Phuong-Chi T Pham
Journal:  Ther Clin Risk Manag       Date:  2008-04       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.